Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

VAXX

Vaxxinity Inc

Apr 19 • 04:00PM ET

0.4761

Dollar change +0.0113
Percentage change 2.43	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VTWO IWC VTWG GERM URTY UWM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.45	Insider Own	64.25%	Shs Outstand	112.87M	Perf Week	-2.28%
Market Cap	60.35M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	45.31M	Perf Month	-32.30%
Income	-56.94M	PEG	-	EPS next Q	-	Inst Own	9.91%	Short Float	9.01%	Perf Quarter	-33.72%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	0.48%	Short Ratio	9.26	Perf Half Y	-51.30%
Book/sh	0.11	P/B	4.50	EPS next Y	-	ROA	-75.49%	Short Interest	4.08M	Perf Year	-77.00%
Cash/sh	0.24	P/C	1.98	EPS next 5Y	-	ROE	-150.65%	52W Range	0.39 - 3.10	Perf YTD	-43.99%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-41.17%	ROI	-213.47%	52W High	-84.64%	Beta	2.53
Dividend TTM	-	Quick Ratio	1.89	Sales past 5Y	-47.04%	Gross Margin	-	52W Low	21.73%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	1.89	EPS Y/Y TTM	24.63%	Oper. Margin	0.00%	RSI (14)	33.49	Volatility	20.07% 11.67%
Employees	57	Debt/Eq	1.13	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	2.00	Target Price	7.00
Option/Short	No / Yes	LT Debt/Eq	0.99	EPS Q/Q	44.61%	Payout	-	Rel Volume	0.88	Prev Close	0.46
Sales Surprise	-	EPS Surprise	10.00%	Sales Q/Q	-	Earnings	Mar 27 AMC	Avg Volume	441.04K	Price	0.48
SMA20	-22.08%	SMA50	-29.73%	SMA200	-61.46%	Trades		Volume	389,253	Change	2.43%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-08-23	Initiated	Robert W. Baird	Outperform	$7
Apr-27-22	Initiated	Evercore ISI	In-line

Today 06:53PM	Vaxxinity Issues Shareholder Letter (GlobeNewswire)
04:27PM	Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock (GlobeNewswire)
Mar-28-24 09:23AM	Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting (GlobeNewswire)
Mar-27-24 10:52PM	VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023 (InvestorPlace) +6.00%
04:41PM	Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
10:32AM	Loading…
Mar-07-24 10:32AM	Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD 2024 (GlobeNewswire) +9.58%
Feb-15-24 11:29AM	Vaxxinitys Heart Health Innovation to Reduce LDL Cholesterol Levels (Exec Edge) -11.09%
08:00AM	Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published (GlobeNewswire)
Feb-13-24 08:00AM	Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 (GlobeNewswire)
Jan-30-24 12:27PM	Vaxxinity, UF Join Forces Against Neurodegenerative Diseases (Exec Edge)
08:00AM	Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida (GlobeNewswire)
Jan-19-24 02:32PM	Vaxxinity & UCF to Collaborate on Space Medicine Research (Exec Edge)
Jan-18-24 08:00AM	Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida (GlobeNewswire)
Jan-03-24 08:00AM	Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference (GlobeNewswire) -9.65%
Nov-20-23 06:00AM	FOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug success (Reuters)
06:50PM	Loading…
Nov-13-23 06:50PM	Vaxxinity to Present at Upcoming November Medical and Investor Conferences (GlobeNewswire) +9.00%
Nov-08-23 08:30AM	Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -9.46%
Sep-07-23 09:35AM	Down -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX) (Zacks)
Aug-29-23 08:00AM	Vaxxinity to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-10-23 05:50PM	Vaxxinity Says UB-311 Shows Potential Advancements in Alzheimers Treatment (Exec Edge)
08:00AM	Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimers Disease (GlobeNewswire)
Aug-09-23 08:00AM	Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-28-23 10:19AM	Vaxxinity Appoints Dr. Peter Powchik as Global Scientific Director (Exec Edge) +5.09%
Jul-27-23 04:30PM	Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director (GlobeNewswire) -5.21%
Jul-17-23 12:23PM	Promising Milestone in Neurodegenerative Disease Treatment: Vaxxinitys UB-312 in Parkinsons Patients (Exec Edge) +10.50%
08:00AM	Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinsons Patients (GlobeNewswire)
Jun-22-23 01:57PM	Vaxxinity Touts Encouraging Data From Early-Stage Parkinson's Vaccine Trial (Benzinga) +8.10%
12:22PM	Positive Phase 1 Results: Vaxxinitys UB-312 Shows Promise in Parkinsons Disease (Exec Edge)
08:00AM	Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinsons Disease (GlobeNewswire)
May-09-23 08:00AM	Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
06:53AM	Loading…
May-03-23 06:53AM	Vaxxinity, Inc.'s (NASDAQ:VAXX) biggest owners are private companies who got richer after stock soared 23% last week (Simply Wall St.)
Apr-24-23 02:09AM	Weekly Biotech Pulse: Vaxxinity results, Biogen's FDA review, and more \| Pro Recap (Investing.com) -5.13%
Mar-28-23 08:00AM	Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April (GlobeNewswire)
Mar-27-23 07:50AM	Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates (GlobeNewswire)
Mar-21-23 08:00AM	Vaxxinity Joins TransCelerate Research and Development Consortium (GlobeNewswire) +16.18%
Mar-20-23 08:00AM	Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia (GlobeNewswire)
Mar-02-23 08:00AM	Vaxxinity to Present at Upcoming March Scientific and Medical Conferences (GlobeNewswire)
Feb-01-23 07:40PM	Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida (GlobeNewswire)
Jan-19-23 02:04PM	Why Shares of Vaxxinity Jumped This Week (Motley Fool) +5.49%
Jan-05-23 08:00AM	Vaxxinity to Present at the 2023 J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-22 07:35AM	Estimating The Fair Value Of Vaxxinity, Inc. (NASDAQ:VAXX) (Simply Wall St.)
Dec-02-22 08:00AM	Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612 (GlobeNewswire) -14.29%
05:30AM	Why Shares of Vaxxinity Soared This Week (Motley Fool)
Nov-10-22 07:30AM	Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-03-22 08:00AM	Vaxxinity to Host First Analyst and R&D Day in New York City on November 10, 2022 (GlobeNewswire)
Nov-01-22 09:00AM	Vaxxinity to Present at Upcoming Investor Conferences in November (GlobeNewswire) +6.06%
Oct-30-22 10:27AM	Vaxxinity, Inc. (NASDAQ:VAXX) stock most popular amongst private companies who own 48%, while individual investors hold 21% (Simply Wall St.)
Oct-24-22 08:00AM	Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia (GlobeNewswire) -6.58%
Sep-19-22 09:00AM	Multiple insiders bought Vaxxinity, Inc. (NASDAQ:VAXX) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Sep-13-22 08:00AM	Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine (GlobeNewswire)
Sep-12-22 08:00AM	Vaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK) (GlobeNewswire)
Sep-01-22 08:00AM	Vaxxinity to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-15-22 04:39PM	UK approves COVID vaccine that targets Omicron subvariants (Yahoo Finance Video)
Aug-12-22 04:19PM	Vaxxinity CEO on COVID: The market isn't going away and it's going to be a massive commercial opportunity (Yahoo Finance)
Aug-11-22 08:00AM	Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates (GlobeNewswire)
Aug-04-22 07:00AM	Vaxxinity to Present at the Canaccord Genuity 42nd Annual Growth Conference (GlobeNewswire) +7.05%
Aug-02-22 01:43PM	Vaxxinity's Vaccine Candidate Shows Durable Cholesterol Lowering Activity In Animal Models (Benzinga) +14.58%
08:00AM	Vaxxinitys Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates (GlobeNewswire)
Aug-01-22 08:00AM	Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates at the 2022 Alzheimer's Association International Conference (AAIC) (GlobeNewswire) +9.71%
Jul-25-22 11:57AM	Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines (GlobeNewswire)
Jun-02-22 07:00AM	Vaxxinity to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
May-12-22 09:31AM	What Percentage Of Vaxxinity, Inc. (NASDAQ:VAXX) Shares Do Insiders Own? (Simply Wall St.)
May-09-22 07:42AM	Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-05-22 07:00AM	Vaxxinity to Participate at the Bank of America Securities 2022 Healthcare Conference (GlobeNewswire) -17.28%
May-02-22 08:00AM	Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimers Disease (GlobeNewswire)
Apr-28-22 08:00AM	Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinsons Disease (GlobeNewswire)
Apr-12-22 08:43AM	Insiders who bought stock earlier this year lose -US$216k as Vaxxinity, Inc. (NASDAQ:VAXX) drops to US$505m (Simply Wall St.)
Apr-07-22 08:14AM	Vaxxinity Receives $9.25M Funding From CEPI To Support Pivotal COVID-19 Vaccine Trial (Benzinga)
Apr-06-22 04:43PM	CEPI to co-fund Vaxxinitys pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants (GlobeNewswire) -5.02%
Mar-28-22 08:00AM	Vaxxinity Announces First Participant Dosed in Phase 3 Study of Next-Generation COVID-19 Vaccine Booster (GlobeNewswire)
Mar-24-22 04:05PM	Vaxxinity Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Updates (GlobeNewswire)
Mar-21-22 07:00AM	Vaxxinity Appoints Dr. Peter Powchik to Board of Directors (GlobeNewswire)
Feb-11-22 09:28AM	Vaxxinitys COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern (GlobeNewswire)
Jan-13-22 10:53AM	Vaxxinity (VAXX) Starts Dosing in Parkinson's Disease Study (Zacks) -9.26%
Jan-12-22 09:21AM	Vaxxinity Announces First Parkinsons Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312 (GlobeNewswire) +29.67%
08:10AM	Vaxxinity Shares Rise After First Patient Dosed in Parkinson's Study (Investing.com)
Jan-10-22 07:00AM	Vaxxinity Awarded Grant from The Michael J. Fox Foundation for Parkinsons Research (MJFF) to Support UB-312 Vaccine Study (GlobeNewswire)
Jan-04-22 07:00AM	Vaxxinity Appoints Jason Pesile as SVP, Finance & Accounting, and George Hornig to Board of Directors (GlobeNewswire)
Dec-23-21 04:45PM	Vaxxinity Reports Third Quarter 2021 Financial Results and Provides Corporate Updates (GlobeNewswire)
Dec-07-21 07:25AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +24.45%
Nov-28-21 07:55AM	Vaxxinity Has a Rough Public Debut (Motley Fool)
Nov-18-21 04:05PM	Vaxxinity Announces Closing of IPO and Partial Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Nov-16-21 12:41PM	Vaxxinity Insider Makes $240K Stock Purchase (Benzinga) -5.19%
Nov-11-21 04:42PM	Vaxxinity, Backblaze Shares Gain in Debuts, but 3 Other IPOs Drop (Barrons.com)
01:59PM	Vaxxinity enjoys warm Wall Street reception as stock trades 20% above IPO price (MarketWatch)
06:43AM	Vaxxinity to go public with $1.6 billion valuation as downsized IPO priced below the expected range (MarketWatch)
06:30AM	Vaxxinity Announces Pricing of Initial Public Offering (GlobeNewswire)

Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company uses its synthetic peptide vaccine platform to harness the immune system and convert the body into its own 'drug factory', stimulating the production of antibodies with a therapeutic effect. Its current pipeline consists of five chronic disease candidates from early to late-stage development across multiple therapeutic areas including Alzheimer's, Parkinson's, migraine and hypercholesterolemia as well as a candidate for COVID-19 prevention. The company was founded by Louis G. Reese IV and Mei Mei Hu in 2014 and is headquartered in Exploration Park, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Prime Movers Lab Fund I LP	10% Owner	Sep 08 '23	Sale	1.67	25,089	41,899	8,713,663	Sep 08 06:05 PM
Prime Movers Lab Fund I LP	10% Owner	Sep 08 '23	Sale	1.67	22,872	38,196	831,658	Sep 08 06:05 PM
Prime Movers Lab Fund I LP	10% Owner	Sep 07 '23	Sale	1.79	20,312	36,302	8,738,752	Sep 08 06:05 PM
Prime Movers Lab Fund I LP	10% Owner	Sep 07 '23	Sale	1.79	18,516	33,092	834,053	Sep 08 06:05 PM
Prime Movers Lab Fund I LP	10% Owner	Sep 06 '23	Sale	1.88	5,308	9,991	8,759,064	Sep 08 06:05 PM
Prime Movers Lab Fund I LP	10% Owner	Sep 06 '23	Sale	1.88	4,839	9,108	835,992	Sep 08 06:05 PM
Diamandis Peter	Director	Apr 26 '23	Option Exercise	0.63	475,537	300,816	906,141	May 02 10:46 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VAXX

Vaxxinity Inc

Upgrade your FINVIZ experience